Engin Altintas is an expert in Gastroenterology at Mersin University (Turkey). As of June 2026, ScienceLeadR ranks Engin Altintas in the top 1% of experts worldwide for Gastroenteritis, and in the top 1% of experts in Turkey for Colitis and Inflammatory Bowel Diseases. Engin Altintas has authored 138 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 4 of them ongoing. SLR score: 559 (community average: 125). How the SLR is computed.

LeadR Profile

Engin Altintas Mersin University Turkey
559 ScienceLeadR Reputation 559
Network Map

Gastroenterology

Subspecialties: Biochemistry - Hepatology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026

Source: PubMed

Mersin University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 138

Citations

Citations: 1 910 1st author: 23 Last author: 32 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Correction: The Impact of Organic Anion-Transporting Polypeptide (OATP) Variants on the Side Effects of Direct-Acting Antivirals in Hepatitis C Patients.
PMID 42222630 — hepatitis c, antiviral agents, hepatitis
Cureus20260
OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV.
PMID 42193057 — hyperbilirubinemia, pharmacogenetics, genotype, therapeutics, antiviral agents, bilirubin
Curr Issues Mol Biol20260
Association of LDLR and SCARB1 gene polymorphisms with hepatocellular carcinoma: a case-control study proposing a 'double-hit' model.
PMID 41965662 — genes, carcinoma, hepatocellular, case-control studies, polymorphism, genetic
Lipids Health Dis20260
A Comparison of the Efficacy and Safety of Ustekinumab and Upadacitinib in Biologically Experienced Ulcerative Colitis Patients.
PMID 41153738 — ustekinumab, colitis, safety, biomarkers, drug-related side effects and adverse reactions, therapeutics, colitis, ulcerative
Biomedicines20250
Epigenetics and Expression of the Wnt Signaling Pathway in Ulcerative Colitis.
PMID 40521787 — genes, colitis, neoplasms, colon, inflammatory bowel diseases, tissues, gastrointestinal diseases, colitis, ulcerative, wnt signaling pathway, frizzled-related proteins
Turk J Gastroenterol20250

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 2 3
Phase 3 3
Phase 2/Phase 3 1

By status:

Recruiting 4
Completed 2
Active not recruiting 1

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
LY4268989 (MORF 057) Co Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07186101 — colitis, colitis, ulcerative
Phase 2Recruiting2025
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn s Disease and Obesity or Overweight
NCT06937099 — crohn disease, obesity, overweight
Phase 3Recruiting2025
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight Phase 3b Study
NCT06937086 — colitis, obesity, therapeutics, overweight, colitis, ulcerative
Phase 3Recruiting2025
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943 — interleukin-23, anti-inflammatory agents, colitis, digestive system diseases, colonic diseases, interleukin-23 subunit p19, inflammatory bowel diseases, intestinal diseases, therapeutics, digestive system, gastrointestinal diseases, ligands, colitis, ulcerative
Phase 2Active not recruiting2024

LeadR Networks

Main global connection map